Osugacestat

DB12006InvestigationalSmall molecule

Osugacestat (BMS-906024) has been used in trials studying the treatment of Cancer, Lymphoblastic Leukemia, Acute T-cell, and Precursor T-Cell Lymphoblastic Lymphoma.

Mechanism: Pharmacologically active on Presenilin-1
Curator reviewed
Formula / weight: C₂₆H₂₆F₆N₄O₃ · 556.509 g/mol (avg)
Code names: AL-101 · BM-0018 · BMS-906024

Resolves to

Compound

UNIIDRL23N424RCAS1401066-79-2ChEMBLCHEMBL4297269ChEBI131164PubChem66550890

Structure

InChIKeyAYOUDDAETNMCBW-GSHUGGBRSA-NSMILESCN1C2=CC=CC=C2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)C1=CC=CC=C1

Targets

P49768PSEN1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Osugacestat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account